A leading company in the e-signature and digital transaction management space, San Francisco-based DocuSign went public in April last year, with a market capitalization of $4.4bn.
GSK, Sphera Global and Medison-backed gene therapy developer Orchard Therapeutics raised $200m in an offering that could possibly close at $230m.
Legend Holdings, Eli Lilly, Ping An, China Life and Taikang-backed Innovent Biologics priced its shares near the top of the range of to raise $421m.
The Pfizer and Gilead-backed immuno-oncology therapy developer, which had raised $300m in an April series A round, floated at the top of its range.
The SoftBank-backed precision oncology test developer floated above its range and saw its share price rise 69% on the first day of trading.
The online survey platform, which counted Alphabet and Salesforce as investors, floated above its range while increasing the number of shares in the IPO.
The Tencent, Baidu, Lenovo and JD.com-backed electric carmaker floated near the foot of its range at a reported $6.4bn valuation.
The Tencent-backed local services portal has priced the offering near the top of its range at a valuation of about $52bn.